BR0311777A - Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina - Google Patents

Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina

Info

Publication number
BR0311777A
BR0311777A BR0311777-4A BR0311777A BR0311777A BR 0311777 A BR0311777 A BR 0311777A BR 0311777 A BR0311777 A BR 0311777A BR 0311777 A BR0311777 A BR 0311777A
Authority
BR
Brazil
Prior art keywords
treatment
vaccine
vesicle composition
neisserial disease
multivalent meningococcal
Prior art date
Application number
BR0311777-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Ramon Faustino Barbera Morales
Pierre Michel Desmons
Francisco Jesus Doming Alvarez
Jan Poolman
Original Assignee
Glaxosmithkline Biolog Sa
Inst Finlay Ct De Investigacio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Inst Finlay Ct De Investigacio filed Critical Glaxosmithkline Biolog Sa
Publication of BR0311777A publication Critical patent/BR0311777A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR0311777-4A 2002-06-13 2003-06-10 Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina BR0311777A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation
PCT/EP2003/006094 WO2003105890A2 (en) 2002-06-13 2003-06-10 Vaccine composition

Publications (1)

Publication Number Publication Date
BR0311777A true BR0311777A (pt) 2005-03-29

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311777-4A BR0311777A (pt) 2002-06-13 2003-06-10 Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina

Country Status (20)

Country Link
US (1) US20060110412A1 (https=)
EP (1) EP1565211A2 (https=)
JP (1) JP2005531614A (https=)
KR (1) KR20050049431A (https=)
CN (1) CN100387298C (https=)
AR (1) AR040204A1 (https=)
AU (1) AU2003236734A1 (https=)
BR (1) BR0311777A (https=)
CA (1) CA2488782A1 (https=)
CL (1) CL2003001192A1 (https=)
CU (1) CU23552A1 (https=)
GB (1) GB0213622D0 (https=)
MX (1) MXPA04012568A (https=)
NO (1) NO20050132L (https=)
NZ (1) NZ560766A (https=)
PE (1) PE20040562A1 (https=)
RU (1) RU2005100509A (https=)
UY (1) UY27843A1 (https=)
WO (1) WO2003105890A2 (https=)
ZA (1) ZA200409547B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2006081259A2 (en) 2005-01-27 2006-08-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
KR101515078B1 (ko) * 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
EP2235531B1 (en) * 2008-02-01 2015-01-14 Sanofi Pasteur Limited Assay for diagnosing streptococcus pneumoniae
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
JP5867952B2 (ja) 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
EP2486940B1 (en) * 2009-10-08 2017-10-04 Aeon Medix Inc. Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (pt) 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
AU2010335970B2 (en) * 2009-12-22 2016-11-03 Sanofi Pasteur Limited Immunogenic compositions
AU2011288203A1 (en) 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
JP6027961B2 (ja) 2010-04-07 2016-11-16 シェン, ユエSHEN, Yue 粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
US9259462B2 (en) * 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP3299467B1 (en) 2012-02-02 2021-08-11 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
AU2013276083B2 (en) 2012-06-14 2018-04-05 Institut Pasteur Vaccines for serogroup X meningococcus
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
MX2023004729A (es) * 2020-10-23 2023-06-29 Omvax Inc Composiciones y metodos de vacunacion contra neisseria gonorrhoeae.
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297072A1 (en) * 1997-07-17 1999-01-28 Baxter Healthcare S.A. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
ES2519440T3 (es) * 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis

Also Published As

Publication number Publication date
NZ560766A (en) 2009-09-25
KR20050049431A (ko) 2005-05-25
GB0213622D0 (en) 2002-07-24
UY27843A1 (es) 2003-12-31
NO20050132L (no) 2005-02-11
CN100387298C (zh) 2008-05-14
AU2003236734A1 (en) 2003-12-31
PE20040562A1 (es) 2004-10-19
MXPA04012568A (es) 2005-09-21
US20060110412A1 (en) 2006-05-25
AR040204A1 (es) 2005-03-16
JP2005531614A (ja) 2005-10-20
EP1565211A2 (en) 2005-08-24
CU23552A1 (es) 2010-07-20
CL2003001192A1 (es) 2005-01-07
CA2488782A1 (en) 2003-12-24
CN1668329A (zh) 2005-09-14
WO2003105890A2 (en) 2003-12-24
NO20050132D0 (no) 2005-01-11
ZA200409547B (en) 2006-07-26
RU2005100509A (ru) 2006-06-10
WO2003105890A3 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
BR0311777A (pt) Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina
BR0212999A (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
EA200901161A1 (ru) Вакцина против гриппа в виде эмульсии типа "масло в воде"
BRPI0409459A (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BRPI0510430A (pt) composições e métodos para vacinação mucosal
CY1111471T1 (el) Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης
BR0213358A (pt) Uso de flibanserina
BR0315767A (pt) Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
BRPI0407950A (pt) processo para a preparação de uma composição de higiene pessoal
NO20070746L (no) Anvendelse av fosfaterte alkanoler som dispergente , emulgatorer, hydrotroper, fuktmidler og kompatabilitetsstoffer i blandinger for jordbruket.
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
BRPI0407742A (pt) uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
BR0208980A (pt) Vacinas incluindo ifn do tipo i como um adjuvante e processos relacionados a esses
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
BRPI0516832A (pt) uso para alfa-simpatomiméticos com uma estrutura de 2-imidazolina
MX2009010963A (es) Vacuna de influenza de emulsion de aceite en agua.
JP2014129251A5 (https=)
ES2173044A1 (es) Glicina, n-(n-l- -glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2258 DE 15/04/2014.